2019
Multidisciplinary strategies to treat severe hypoglycemia in hospitalized patients with diabetes mellitus reduce inpatient mortality rate: Experience from an academic community hospital
Kadayakkara D, Balasubramanian P, Araque K, Davis K, Javed F, Niaki P, Majumdar S, Buller G. Multidisciplinary strategies to treat severe hypoglycemia in hospitalized patients with diabetes mellitus reduce inpatient mortality rate: Experience from an academic community hospital. PLOS ONE 2019, 14: e0220956. PMID: 31393971, PMCID: PMC6687156, DOI: 10.1371/journal.pone.0220956.Peer-Reviewed Original ResearchConceptsPatient mortality ratesSevere hypoglycemiaReadmission ratesDiabetes mellitusMortality rateNotification ratesStandardized treatmentGeneral internal medicine wardsMultidisciplinary strategyPatient's medical teamInpatient mortality rateInternal medicine wardsICD-10 codesPost-intervention studyStandardization of treatmentGlucose measurementsAcademic community hospitalSame observation periodDiabetic patientsHospitalized patientsMedicine wardsRetrospective reviewPhysician notificationPoor outcomeSecondary diagnosisProinsulin Expressing Neuroendocrine Tumors of the Pancreas
Celli R, Tang LH, Cai G, Freedman-Weiss M, Colunga M, Salem RR, Majumdar S, Jain D. Proinsulin Expressing Neuroendocrine Tumors of the Pancreas. Pancreas 2019, 48: 55-59. PMID: 30451800, DOI: 10.1097/mpa.0000000000001196.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsPancreatic neuroendocrine tumorsNeuroendocrine tumorsAvailable clinicopathologic dataIHC-negative tumorsSurgical oncology centersNormal insulin levelsIHC-positive tumorsSerum proinsulinClinicopathologic featuresPNET patientsClinicopathologic dataHypoglycemic patientsInsulin levelsProspective studyOncology centersSerum glucoseSuch tumorsClinical significanceInsulin immunohistochemistryRare casePatientsImmunohistochemistryProinsulinomaTumorsInsulinoma
2017
A Systematic Review of Proinsulin-Secreting Pancreatic Neuroendocrine Tumors
Murtha TD, Lupsa BC, Majumdar S, Jain D, Salem RR. A Systematic Review of Proinsulin-Secreting Pancreatic Neuroendocrine Tumors. Journal Of Gastrointestinal Surgery 2017, 21: 1335-1341. PMID: 28510792, DOI: 10.1007/s11605-017-3428-8.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsPancreatic neuroendocrine tumorsNeuroendocrine tumorsSystematic reviewRare pancreatic neuroendocrine tumorYale-New Haven HospitalMajority of patientsMedian tumor diameterLower insulin levelsBiomedical databases PubMedNew Haven HospitalSymptomatic hypoglycemiaMost patientsFemale predominanceTumor diameterClinicopathologic featuresInsulin levelsUncommon diseaseMean ageOvid MEDLINEHormonal levelsDatabases PubMedPatientsProinsulinomaHormone productionTumors
2016
Current Therapies for the Medical Management of Diabetes
Inzucchi SE, Majumdar SK. Current Therapies for the Medical Management of Diabetes. Obstetrics And Gynecology 2016, 127: 780-794. PMID: 26959197, DOI: 10.1097/aog.0000000000001332.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2014
Glycemic Targets What is the Evidence?
Inzucchi S, Majumdar S. Glycemic Targets What is the Evidence? Medical Clinics Of North America 2014, 99: 47-67. PMID: 25456643, DOI: 10.1016/j.mcna.2014.08.018.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsComplications of diabetesGlucose hypothesisStrong epidemiologic associationGlycemic targetsDiabetes mellitusGlucose loweringMetabolic abnormalitiesMajor trialsEpidemiologic associationGlucose levelsClinical practiceHyperglycemiaEpidemiologic relationshipComplicationsDiabetesMellitusAbnormalitiesDiagnosisTrials
2013
Targeting Pyruvate Carboxylase Reduces Gluconeogenesis and Adiposity and Improves Insulin Resistance
Kumashiro N, Beddow SA, Vatner DF, Majumdar SK, Cantley JL, Guebre-Egziabher F, Fat I, Guigni B, Jurczak MJ, Birkenfeld AL, Kahn M, Perler BK, Puchowicz MA, Manchem VP, Bhanot S, Still CD, Gerhard GS, Petersen KF, Cline GW, Shulman GI, Samuel VT. Targeting Pyruvate Carboxylase Reduces Gluconeogenesis and Adiposity and Improves Insulin Resistance. Diabetes 2013, 62: 2183-2194. PMID: 23423574, PMCID: PMC3712050, DOI: 10.2337/db12-1311.Peer-Reviewed Original ResearchConceptsPyruvate carboxylaseAntisense oligonucleotideHepatocyte fatty acid oxidationInsulin resistanceNonalcoholic fatty liver diseaseZucker diabetic fatty ratsHigh fat-fed ratsFatty liver diseaseLiver biopsy specimensDiabetic fatty ratsPlasma lipid concentrationsType 2 diabetesHepatic insulin sensitivityHuman liver biopsy specimensEndogenous glucose productionHepatic insulin resistancePlasma glucose concentrationPotential therapeutic approachSpecific antisense oligonucleotideFat-fed ratsCarboxylaseFatty acid oxidationDe novo fatty acid synthesisLiver diseaseTissue-specific inhibitionRole of patatin‐like phospholipase domain‐containing 3 on lipid‐induced hepatic steatosis and insulin resistance in rats
Kumashiro N, Yoshimura T, Cantley JL, Majumdar SK, Guebre‐Egziabher F, Kursawe R, Vatner DF, Fat I, Kahn M, Erion DM, Zhang X, Zhang D, Manchem VP, Bhanot S, Gerhard GS, Petersen KF, Cline GW, Samuel VT, Shulman GI. Role of patatin‐like phospholipase domain‐containing 3 on lipid‐induced hepatic steatosis and insulin resistance in rats. Hepatology 2013, 57: 1763-1772. PMID: 23175050, PMCID: PMC3597437, DOI: 10.1002/hep.26170.Peer-Reviewed Original ResearchInvestigational anti-hyperglycemic agents: the future of type 2 diabetes therapy?
Majumdar SK, Inzucchi SE. Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy? Endocrine 2013, 44: 47-58. PMID: 23354728, DOI: 10.1007/s12020-013-9884-3.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsType 2 diabetesGlucose loweringCurrent therapiesFree Fatty Acid Receptor AgonistsNewer incretin-based therapiesGlucose cotransporter 2 inhibitorsDurable glycemic controlCotransporter 2 inhibitorsIncretin-based therapiesType 2 diabetes therapyIndividual patient characteristicsAcid receptor agonistsNew therapeutic classDiverse patient populationsMechanism of actionInsulin useComplex regimensPatient characteristicsGlycemic controlPatient populationType 1 inhibitorNatural courseReceptor agonistClinical trialsTreatment choice